Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

Journal of Clinical Oncology

Volumn 19, Issue 6, 2001, Pages 1743-1749

  Von Pawel, J ^a   Gatzemeier, U ^a   Pujol, J L ^a   Moreau, L ^a   Bildat, S ^a   Ranson, M ^a   Richardson, G ^a   Steppert, C ^a   Riviere A ^a   Camlett, I ^a   Lane, S ^a   Ross, G ^a  

^a ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEVER; HUMAN; INFECTION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIORITY JOURNAL; SEPSIS; SURVIVAL RATE; VOMITING;

EID: 0035868768     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.6.1743     Document Type: Article

References (13)

1. Therapy of small cell lung cancer: A perspective on two decades of clinical research
2. Topoisomerase 1 inhibitors: Topotecan and irinotecan
3. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer SCLC: A phase II study in patients with refractory and sensitive disease
4. Evaluation of topotecan (Hycamtin) in relapsed small-cell lung cancer (SCLC): A multicentre phase II study
5. Topotecan (T) as second-line therapy in patients (pts) with small cell lung cancer (SCLC): A phase II study
6. Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer
7. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
8. Topotecan (T) versus (vs) cyclophosphamide (C), doxorubicin (A) and vincristine (V) for the treatment (tx) of patients (pts) with recurrent small cell lung cancer (SCLC): A phase III study
9. 5 Days of once daily oral topotecan, a phase I and pharmacologic study in adults
10. Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale
11. A phase II study of 5-fluorouracil plus high-dose folinic acid in the treatment of recurrent small cell lung cancer
12. Phase II study of carboplatin and Adriamycin as second line chemotherapy in small cell lung cancer
13. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study